State lawmakers have approved legislation, Senate Bill 155, to fund observational and clinical research assessing the safety and therapeutic efficacy of cannabis. Democrat Gov. John Hickenlooper signed the bill into law.
The measure establishes a subaccount of up to $10 million within the state’s medical marijuana program fund to be utilized specifically for the purpose of conducting state-sponsored cannabis research. The intent of this new research program is to “gather objective scientific research regarding the efficacy of administering marijuana and its component parts as part of medical treatment.” The law also establishes a ‘scientific advisory council,’ which may include expert participants from around the nation, to evaluate research proposals and make recommendations in regards to funding requests.
“SB 155 invests the dollars collected from medical marijuana fees into a meaningful effort to study the therapeutic and medical benefits of the drug,” stated Democrat Rep. Crisanta Duran, a co-sponsor of the bill, told The Huffington Post. “Patients will benefit from this investment and Colorado will become a national leader in developing medical marijuana research.”
In recent years, only one state — California — has previously earmarked state funding to explicitly sponsor clinical cannabis research. That program, established at various universities statewide, funded numerous clinical trials over the past decade evaluating the efficacy of whole-plant cannabis for a variety of conditions, including multiple sclerosis and neuropathic pain. A review of these trials published in The Open Neurology Journal concluded, “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.”
Earlier this month, the US Drug Enforcement Administration (DEA) publicly announced in the Federal Register that it is increasing its marijuana production quota from 21 kilograms to 650 kilograms (about 1,443 pounds) in order to meet increasing demand for the plant from clinical investigators.
Federal regulations permit a farm at the University of Mississippi to cultivate set quantities of cannabis for use in federally approved clinical trials. Regulators at the DEA, the US Food and Drug Administration, PHS (Public Health Service), and the US National Institute on Drug Abuse must approve any clinical protocol seeking to study the plant’s effects in human subjects — including those trials that are either state or privately funded.